Simultaneous treatment with palm-LEAP2(1-14) and feeding high-fat diet attenuates liver lipid metabolism but not obesity: Sign of selective resistance to palm-LEAP2(1-14)
Language English Country Ireland Media print-electronic
Document type Journal Article
PubMed
39689753
DOI
10.1016/j.mce.2024.112442
PII: S0303-7207(24)00298-3
Knihovny.cz E-resources
- Keywords
- Diet-induced obesity, Ghrelin, LEAP2, LEAP2 resistance, Lipid metabolism, Palm-LEAP2(1–14),
- MeSH
- Diet, High-Fat * adverse effects MeSH
- Ghrelin pharmacology MeSH
- Liver * metabolism drug effects MeSH
- Antimicrobial Cationic Peptides MeSH
- Blood Proteins MeSH
- Lipogenesis drug effects MeSH
- Lipid Metabolism * drug effects MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Obesity * metabolism drug therapy MeSH
- Peptide Fragments * pharmacology pharmacokinetics MeSH
- Receptors, Ghrelin metabolism MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Ghrelin MeSH
- Antimicrobial Cationic Peptides MeSH
- Blood Proteins MeSH
- liver-expressed antimicrobial peptide 2, human MeSH Browser
- Peptide Fragments * MeSH
- Receptors, Ghrelin MeSH
Liver-enriched antimicrobial peptide 2 (LEAP2) is a natural antagonist/inverse agonist of ghrelin receptor GHSR. Its truncated palmitoylated analog palm-LEAP2(1-14) promised anti-obesity properties because it exhibited favourable stability and an acute anorexigenic effect in our previous studies. Here we demonstrate desirable palm-LEAP2(1-14) pharmacokinetics, with significant levels of the peptide persisting in mouse blood 3 h after its subcutaneous administration. Palm-LEAP2 (1-14) reduced ghrelin-induced c-Fos immunoreactivity in arcuate nucleus and area postrema, in line with previously described silencing of ghrelin orexigenic effect. In spite of this, anti-obesity effect was not reached by two-week palm-LEAP2(1-14) treatment in mice with diet-induced obesity. Similarly, palm-LEAP2(1-14) administered simultaneously with high-fat diet feeding for 8 weeks did not protect mice from development of obesity and related biochemical changes. However, palm-LEAP2(1-14) kept its ability to attenuate liver de novo lipogenesis, and prominently lowered liver gene expression of nuclear receptors PPARG, SREBF1 and PPARA, and also expression of lipogenic and lipolytic enzymes. In our recent study, we described a high-fat diet-induced ghrelin resistance, reversible by switch to standard diet, followed by resistance to the acute anorexigenic effects of palm-LEAP2(1-14). Here we conclude that this resistance to palm-LEAP2(1-14) in obesity is probably selective and does not concern its ability to inhibit liver lipid metabolism.
IBMM University of Montpellier CNRS ENSCM Montpellier France
Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Prague Czech Republic
University of Chemistry and Technology Prague Czech Republic
References provided by Crossref.org
